You are reading 1 of 2 free-access articles allowed for 30 days
The stock currently held by the Executive is due to expire by the end of this year or early next year.
“The Tamiflu stock is due to expire late 2016/2017,” an Executive spokesperson told the Medical Independent (MI). “Discussions are ongoing whether further stockpiles are needed.”
The HSE did not provide figures on how much the stockpile is worth.
MI reported in February 2014 that the HSE had €2.5 million worth of Tamiflu in stock at that time.
The drug’s effectiveness has been questioned by some medical organisations and publications in recent years, however, last week the Executive spokesperson defended the drug.
“The Tamiflu effectiveness is fully supported by WHO, CDC in the US and PHE in the UK, as well as ECDC,” the HSE spokesperson told MI.
“The antiviral medicines like Tamiflu and Relenza are used to treat the symptoms of flu and to try to reduce their severity,” reads the HSE website.